494772-02-0

Basic information

• Product Name: 5-bromo-2-(cyclopropylmethoxy)pyridine
• Synonyms: 5-bromo-2-(cyclopropylmethoxy)pyridine
• CAS NO: 494772-02-0
• Molecular Formula: C9H10BrNO
• Molecular Weight: 228.088
• Mol File: 494772-02-0.mol
• Article Data: 13

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 5-bromo-2-(cyclopropylmethoxy)pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-bromo-2-(cyclopropylmethoxy)pyridine(494772-02-0)
• EPA Substance Registry System: 5-bromo-2-(cyclopropylmethoxy)pyridine(494772-02-0)

Safety Data

• Hazardous Substances Data: 494772-02-0(Hazardous Substances Data)

Usage

General Description

5-bromo-2-(cyclopropylmethoxy)pyridine is a chemical compound with the molecular formula C8H8BrNO, and a molar mass of 217.06 g/mol. It is a heterocyclic aromatic compound containing a bromine atom, a pyridine ring, and a cyclopropylmethoxy group. 5-bromo-2-(cyclopropylmethoxy)pyridine is often used as a building block in organic synthesis and pharmaceutical research. It has potential applications in the development of new drugs and agrochemicals due to its unique structure and reactivity. Additionally, its cyclopropyl group can serve as a valuable synthetic handle for further functionalization, making it a versatile tool for creating complex organic molecules.

Upstream product

• 624-28-2 2,5-dibromopyridine 
• 2516-33-8 Cyclopropylmethanol 
• 766-11-0 5-bromo-2-fluoropyridine 

Downstream Products

• 1224719-40-7 6-(2-cyclopropylmethoxy)pyridin-3-ol 
• 1344684-96-3 2-(cyclopropylmethoxy)-5-(methoxymethoxy)pyridine-4-carboxylic acid 
• 1443668-87-8 (S)-N-(1-(4-(1-(6-(cyclopropylmethoxy)pyridin-3-yl)azetidin-3-yloxy)phenyl)ethyl)-acetamide 
• 947191-69-7 2-(cyclopropylmethoxy)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine 

Relevant articles and documents

INHIBITORS OF TRPC6

The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts therefore, wherein R1 to R6, A, U, V, W, X, Y, and Z are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

SUBSTITUTED FUSED HETEROCYCLES AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS

The present invention relates to substituted fused heterocyclic compounds. The substituted fused heterocyclic compounds are GPR1 19 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The invention furthermore relates to the use of substituted fused heterocyclic compounds as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.

SUBSTITUTED INDANONE COMPOUNDS AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS

The present invention relates to indanone compounds. The indanone compounds are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The invention furthermore relates to the use of inda